Skandinaviska Enskilda Banken Ab (Publ) Novavax Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$36.28 - $75.29 $383,515 - $795,890	-10,571 Reduced 94.84%	575 $30,000
Q1 2022 May 11, 2022	BUY	$69.73 - $142.9 $33,121 - $67,877	475 Added 4.45%	11,146 $821,000
Q4 2021 Feb 10, 2022	SELL	$134.56 - $217.97 $1.8 Million - $2.92 Million	-13,386 Reduced 55.64%	10,671 $1.65 Million
Q3 2021 Nov 10, 2021	SELL	$177.8 - $270.58 $25,247 - $38,422	-142 Reduced 0.59%	24,057 $4.99 Million
Q2 2021 Aug 10, 2021	BUY	$121.0 - $257.67 $2.91 Million - $6.2 Million	24,049 Added 16032.67%	24,199 $5.14 Million
Q3 2020 Nov 12, 2020	SELL	$79.44 - $178.51 $47,664 - $107,106	-600 Reduced 80.0%	150 $16,000
Q1 2020 Jun 05, 2020	BUY	$3.93 - $16.0 $2,947 - $12,000	750 New	750 $10,000

291

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $704M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.